Intercept Pharmaceuticals Inc (ICPT)

Add to Watchlists

Create an Alert

Quickflows

45.64 +1.78 +4.06% NASDAQ Jul 10, 11:39 Delayed 2m USD

Intercept Pharmaceuticals News

Wire

Headline

Time (ET)
Yahoo

Biogen Stock Is Jumping. The Biotech Submitted Its Troubled Alzheimer’s Drug for FDA Approval.

07/08 10:13
Yahoo

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

07/02 14:25
Yahoo

FDA Rejects Intercept’s Liver Disease Drug, But This Analyst Still Anticipates Approval

07/02 11:27
Yahoo

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

07/01 18:55
Yahoo

Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More

07/01 09:43
Yahoo

Should You Throw in the Towel on Intercept Pharmaceuticals After Its Big Setback?

07/01 07:02
Yahoo

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

06/30 21:06
SA Breaking News

Heavy upside, catalysts ahead in liver disease space for Needham

06/30 17:52
MT Newswires

Analyst Actions: Citigroup Upgrades Intercept Pharmaceuticals to Buy From Neutral

06/30 11:46
MT Newswires

--Analyst Actions: Credit Suisse Downgrades Intercept Pharmaceuticals to Neutral From Outperform, PT Cut to $59 From $137

06/30 10:50
Yahoo

Intercept Slumps as the FDA Issues CRL to NASH Candidate

06/30 10:29
Yahoo

Company News for Jun 30, 2020

06/30 09:35
MT Newswires

--Analyst Actions: Raymond James Downgrades Intercept Pharmaceuticals to Market Perform From Outperform

06/30 09:18
MT Newswires

--Analyst Actions: Goldman Sachs Downgraded Intercept Pharmaceuticals to Neutral From Buy, Drops PT to $60 From $150

06/30 09:17
MT Newswires

Analyst Actions: SVB Leerink Cuts Price Target on Intercept Pharmaceuticals to $50 From $89, Maintains Market Perform Rating

06/30 09:14
MT Newswires

Analyst Actions: HC Wainwright Cuts Intercept Pharmaceuticals PT to $48 From $92, Maintains Neutral Rating

06/30 09:13
MT Newswires

--Analyst Actions: UBS Cuts Intercept Pharmaceuticals to Neutral From Buy, Price Target to $57 From $135

06/30 09:12
MT Newswires

Analyst Actions: Chardan Cuts Intercept Pharmaceuticals' Price Target to $105 From $145, Keeps Rating at Buy

06/30 08:25
MT Newswires

--Analyst Actions: Cowen Downgrades Intercept Pharmaceuticals to Market Perform From Outperform; Price Target is $47

06/30 06:47
MT Newswires

Analyst Actions: Cantor Fitzgerald Downgrades Intercept Pharmaceuticals to Neutral From Overweight

06/30 06:45

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial

{{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.